Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine

1996 ◽  
Vol 50 (1-2) ◽  
pp. 121-128 ◽  
Author(s):  
G. Muralidharan ◽  
J. K. Cooper ◽  
E. M. Hawes ◽  
E. D. Korchinski ◽  
K. K. Midha
Keyword(s):  
Extensive Metabolisers

Haemodynamic Effects of Nebivolol in Poor and Extensive Metabolisers

1991 ◽  
Vol 3 (S1) ◽  
pp. 161-163
Author(s):  
P. Rooy ◽  
J. Crée
Keyword(s):  
Haemodynamic Effects ◽  
Extensive Metabolisers

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

Pain ◽  
1993 ◽  
Vol 53 (3) ◽  
pp. 335-339 ◽  
Author(s):  
Søren H. Sindrup ◽  
Lars Poulsen ◽  
Kim Brøsen ◽  
Lars Arendt-Nielsen ◽  
Lars F. Gram
Keyword(s):  
Poor Metabolisers ◽  
Extensive Metabolisers

scholarly journals Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e038031
Author(s):  
Tae-Jin Song ◽  
Jinkwon Kim ◽  
Sang Won Han ◽  
Young Dae Kim ◽  
Jong Yun Lee ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Cardiovascular Events ◽  
Antiplatelet Agent ◽  
Institutional Review Board ◽  
Loss Of Function ◽  
Extensive Metabolisers ◽  
Institutional Review ◽  
Cytochrome P450 2C19

IntroductionClopidogrel is an antiplatelet agent that is widely used for the secondary prevention of cardiovascular and cerebrovascular events. The genotype of cytochrome P450 2C19 (CYP2C19) differentially affects the liver’s metabolism of clopidogrel, which may influence the drug’s response and efficacy for cardiovascular event prevention. In contrast to prior studies of patients with coronary artery diseases, little is known about whether the CYP2C19 genotype influences the preventive efficacy of clopidogrel in patients who had a stroke. We hypothesise that, among patients who had an acute ischaemic stroke who are prescribed clopidogrel, the patients with a loss-of-function CYP2C19 genotype (poor and intermediate metabolisers) may be at a higher risk of composite cardiovascular events than those who are non-carriers (extensive metabolisers).Methods and analysisThis prospective observational multicentre study was designed to determine whether composite cardiovascular events would differ among patients who had an ischaemic stroke prescribed clopidogrel according to CYP2C19 genotype (poor or intermediate vs extensive metabolisers). Inclusion criteria were patients who had an acute ischaemic stroke who underwent CYP2C19 genotype evaluation and received clopidogrel within 72 hours of stroke onset. The primary outcome is composite cardiovascular events (stroke, myocardial infarction, or cardiovascular death) within 6 months after acute ischaemic stroke between patients categorised as poor or intermediate metabolisers and those categorised as extensive metabolisers according to their CYP2C19 genotype.Ethics and disseminationThe Institutional Review Board of Severance Hospital, Yonsei University College of Medicine approved this study (3-2019-0195). We received study approval from the institutional review board of each participating hospital. We plan to disseminate our findings at relevant conferences and meetings and through peer-reviewed journals.Trial registration numberNCT04072705.

DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers

1994 ◽  
Vol 94 (4) ◽  
Author(s):  
S. Panserat ◽  
C. Mura ◽  
N. G�rard ◽  
M. Vincent-Viry ◽  
M.M. Galteau ◽  
...  
Keyword(s):  
Amino Acid ◽  
Amino Acid Sequence ◽  
Extensive Metabolisers

CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Dmitriy V. Ivashchenko ◽  
Daria A. Yudelevich ◽  
Nina I. Buromskaya ◽  
Pavel V. Shimanov ◽  
Roman V. Deitch ◽  
...  
Keyword(s):  
Treatment Efficacy ◽  
Gene Polymorphisms ◽  
Haplotype Analysis ◽  
Drug Effects ◽  
Efficacy And Safety ◽  
Adverse Drug Effects ◽  
Extensive Metabolisers ◽  
Intermediate Metabolism ◽  
Brief Psychotic Disorder ◽  
Icd 10

Abstract Objectives To identify possible associations of CYP2D6, CYP3A4/5, and ABCB1 gene polymorphisms with the efficacy and safety of antipsychotics in adolescents with acute psychotic episodes. Methods We examined the associations of pharmacogenetic factors with the efficacy and safety of antipsychotics in 101 adolescents with acute psychotic episodes. The diagnosis on admission was “Brief psychotic disorder” (F23.0–23.9 by ICD-10). All patients were administered antipsychotics for 14 days. Treatment efficacy and safety were assessed using the PANSS, CGAS, CGI-S(I), UKU SERS, BARS, and SAS scales. Pharmacokinetic genotyping was performed for the CYP2D6*4, *10, ABCB1 1236C>T, 2677G>T, and 3435C>T genes. Results CYP2D6 intermediate metabolisers had “Micturition disturbances” more often than extensive metabolisers (24.2 vs. 7.4%; p=0.026). “Wild” homozygote ABCB1 3435C>T CC was associated with more prominent akathisia. Haplotype analysis of three ABCB1 polymorphisms revealed that the “wild” alleles “C-G-C” (ABCB1 1236-2677-3435) were associated with higher risk of “Reduced salivation” (OR=2.95; 95% CI=1.35–6.45; p=0.0078). Conclusions CYP2D6 intermediate metabolism was associated with the risk of urinary difficulties under treatment with antipsychotics. We found that “wild” homozygotes ABCB1 1236C>T, 2677G>T, and 3435C>T were predictors of adverse drug effects caused by treatment with antipsychotics.

Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?

2020 ◽  
Vol 76 (8) ◽  
pp. 1143-1150 ◽  
Author(s):  
Manoranjenni Chetty ◽  
Michael P. Danckwerts ◽  
Andrea Julsing
Keyword(s):  
Extensive Metabolisers ◽  
Daily Dose ◽  
In Pregnancy

Timolol Metabolism in Poor and Extensive Metabolisers of Debrisoquine

1985 ◽  
Vol 68 (s11) ◽  
pp. 51P-51P
Author(s):  
J C Mcgourty ◽  
J H Silas ◽  
J J Fleming ◽  
A McBurney ◽  
J W Ward
Keyword(s):  
Extensive Metabolisers

Acid-suppressive effects of rabeprazole: Comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers

2006 ◽  
Vol 38 (11) ◽  
pp. 802-808 ◽  
Author(s):  
T. Shimatani ◽  
M. Moriwaki ◽  
J. Xu ◽  
S. Tazuma ◽  
M. Inoue
Keyword(s):  
Helicobacter Pylori ◽  
Extensive Metabolisers

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers

2005 ◽  
Vol 61 (7) ◽  
pp. 551-554 ◽  
Author(s):  
Rafael de la Torre ◽  
Magí Farré ◽  
Brian Ó Mathúna ◽  
Pere N. Roset ◽  
Neus Pizarro ◽  
...  
Keyword(s):  
Poor Metaboliser ◽  
Extensive Metabolisers
Sign in / Sign up

Export Citation Format

Share Document